The study examines missed cases in genomic newborn screening, addressing decision-making in screening program limits and scope.
Newson and colleagues helpfully move the debate about “missed cases” in genomic newborn screening (gNBS) from the genome itself to a feature of the screening programme [ 1 ]. On their account, a missed case is not simply a condition waiting passively in the data, but something produced by decisions about programme scope and the limits of what a population screening programme is justified in looking for. This helps shift discussion away from the idea that genomic technology can or should detect everything, and towards the more realistic question of how screening programmes define, communicate, and govern their remit.
No takes yet. Share an insight, caveat, or question.
Carley et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: